Regulatory Compliance and Risk Management in Pharmaceuticals and Healthcare
DOI:
https://doi.org/10.47941/ijhs.2223Keywords:
Regulatory Compliance, Pharmaceutical Industry, Healthcare Industry, Accelerated Pharmaceutical Development (APD), Compliance Strategies, Risk MitigationAbstract
Purpose: This study aims to examine the evolving regulatory landscape and its impact on compliance and risk management within the pharmaceutical and healthcare industries. It seeks to identify effective strategies for maintaining data integrity and traceability in accelerated pharmaceutical development (APD), and to understand how these strategies improve patient care and healthcare system responsiveness.
Methodology: The research involves a comprehensive review of current regulations, emerging trends, and industry practices. It utilizes an analysis of regulatory updates, risk management frameworks, and case studies to illustrate successful compliance strategies and the challenges faced by organizations.
Findings: The study highlights key regulatory requirements, identifies common risks and mitigation strategies, and provides insights into effective practices for ensuring data integrity and traceability. It demonstrates that robust compliance and risk management practices contribute to enhanced patient outcomes and improved healthcare system efficiency.
Unique Contribution to Theory, Policy, and Practice: This research offers a detailed examination of the intersection between regulatory compliance and risk management, providing a valuable framework for understanding and addressing the complexities of the pharmaceutical and healthcare sectors. It contributes to theory by integrating recent regulatory changes with practical risk management approaches, informs policy by highlighting critical areas for regulatory focus, and offers actionable recommendations for industry practitioners to optimize compliance and data management processes.
Downloads
References
Adedayo, M. (2023). Evaluating the Influence of Regulatory Compliance on Operational Risks in Healthcare. International Journal of Modern Risk Management, 1(1).
Agarwal, V., Gupta, O., Priyadarshini, K., & Agrawal, S. A Failure of Regulatory Diligence: A Case Study of Ranbaxy Laboratories Ltd.
Allen, M. E., & Vandenburg, M. J. (1992). Good clinical practice: rules, regulations and their impact on the investigator. British journal of clinical pharmacology, 33(5), 463.
Annisa, V. (2022). Good Laboratory Practice (GLP) in The European Union. Indonesian Journal of Pharmaceutical Education, 2(1), 1-9.
Arnold, M. (2004). Directing compliance: patient non-compliance in the statin category alone costs pharma companies billions in lost revenues. Matthew Arnold looks at how Pfizer and others are pushing the boundaries of relationship marketing to keep patients on board and on track. Medical Marketing & Media, 39(6), 36-42.
Arnold, V., Benford, T., Canada, J., & Sutton, S. G. (2011). The role of strategic enterprise risk management and organizational flexibility in easing new regulatory compliance. International Journal of accounting information systems, 12(3), 171-188.
Berry, I. R. (2013). Good Manufacturing Practices (GMPs)–An Overview. v Encyclopedia of Pharmaceutical Technology, 3, 1941-1947.
Cavers, D. F. (1939). The Food, Drug, and Cosmetic Act of 1938: its legislative history and its substantive provisions. Law & Contemp. Probs., 6, 2.
Daemmrich, A. (2011). US healthcare reform and the pharmaceutical industry.
Das, R. K., & Drolet, B. C. (2022). Lessons from Theranos–Restructuring Biomedical Innovation. Journal of Medical Systems, 46(5), 25.
Dill, A. (2019). Bank regulation, risk management, and compliance: theory, practice, and key problem areas. informa law from Routledge.
Du, P., & Kofman, J. A. (2007). Electronic laboratory notebooks in pharmaceutical R&D: on the road to maturity. JALA: Journal of the Association for Laboratory Automation, 12(3), 157-165.
Eaddy, L. L. (2012). Johnson & Johnson's Recall Debacle.
Edwards, B., & Chakraborty, S. (2012). Risk communication and the pharmaceutical industry: what is the reality?. Drug safety, 35, 1027-1040.
Emmert, M. H., Christensen, M., DiRocco, D. A., Dreher, S. D., Isom, D. C., Isom, R., & Shevlin, M. (2022). Inventing and Building HTE Technology for End-Users: The Merck/Analytical Sales and Services Collaboration—An Interview. In The Power of High-Throughput Experimentation: General Topics and Enabling Technologies for Synthesis and Catalysis (Volume 1) (pp. 87-104). American Chemical Society.
Goodrich, W. W. (1963). FDA's Regulation under the Kefauver-Harris Drug Amendments of 1962. Food Drug Cosm. LJ, 18, 561.
Handoko, B. L., Riantono, I. E., & Gani, E. (2020). Importance and Benefit of Application of Governance Risk and Compliance Principle. Systematic Reviews in Pharmacy, 11(9).
Harrison, J. S., McGowan, R., O'Neill, K., Shotwell, L., & Torres, J. (2017). Pfizer.
He, T. T., Ung, C. O. L., Hu, H., & Wang, Y. T. (2015). Good manufacturing practice (GMP) regulation of herbal medicine in comparative research: China GMP, cGMP, WHO-GMP, PIC/S and EU-GMP. european Journal of integrative Medicine, 7(1), 55-66.
Hopkins, A. (2011). Risk-management and rule-compliance: Decision-making in hazardous industries. Safety science, 49(2), 110-120.
Jena, G. B., & Chavan, S. (2017). Implementation of Good Laboratory Practices (GLP) in basic scientific research: Translating the concept beyond regulatory compliance. Regulatory Toxicology and Pharmacology, 89, 20-25.
Kantor, A. F. (1976). Upton Sinclair and the Pure Food and Drugs Act of 1906." I aimed at the public's heart and by accident I hit it in the stomach". American Journal of Public Health, 66(12), 1202-1205.
Karmacharya, J. B. (2014). Good manufacturing practices (GMP) for medicinal products. Promising Pharmaceuticals, 101.
Kesselheim, A. S., Sinha, M. S., Avorn, J., & Sarpatwari, A. (2019). Pharmaceutical policy in the United States in 2019: An overview of the landscape and avenues for improvement. Stan. L. & Pol'y Rev., 30, 421.
Kleczyk, E. (2008). Risk management in the development of new products in the pharmaceutical industry.
Mowla, M. M., Hoque, N., Mamun, A., & Uddin, M. R. (2014). Entry Mode Selection, Location Choice and the Sequence of Internationalization: A Case Study on Ranbaxy Laboratories Ltd. Asian Social Science, 10(6), 145.
Muralidharan, S. Impact of cross border mergers and acquisitions (M&A) in pharmaceutical R&D: a case study of Ranbaxy laboratories. SOUTH ASIAN S SOUTH ASIAN STUDIES, 89.
Murray, E., & Shohen, S. (1992). Lessons from the Tylenol tragedy on surviving a corporate crisis. Medical Marketing & Media, 27(2), 14-18.
Niv, Y., & Tal, Y. (2024). Risk Management and Patient Safety Processes in a Healthcare Organization. In Patient Safety and Risk Management in Medicine: From Theory to Practice (pp. 129-174). Cham: Springer Nature Switzerland.
Norhaslinda, R., Norhayati, A., & Mohd, A. (2016). Knowledge, attitudes and practices (KAP) on good manufacturing practices (GMP) among food handlers in Terengganu hospitals. Int. J. Pharm. Pharm. Sci, 8, 53-59.
O'Connor, U., Carinou, E., Clairand, I., Ciraj-Bjelac, O., De Monte, F., Domienik-Andrzejewska, J., ... & Vanhavere, F. (2021). Recommendations for the use of active personal dosemeters (APDs) in interventional workplaces in hospitals. Physica medica, 87, 131-135.
Ojji, S. O. (2024). Emerging Technology Integration-Artificial Intelligence (AI) and Machine Learning (ML) for Predictive Analysis for Safety and Toxicity Assessment in Environmental Toxicology. Valley International Journal Digital Library, 1182-1195.
Oldenkamp, R., Hamers, T., Wilkinson, J., Slootweg, J., & Posthuma, L. (2024). Regulatory risk assessment of pharmaceuticals in the environment: Current practice and future priorities. Environmental toxicology and chemistry, 43(3), 611-622.
Ozaki, A., Saito, H., Senoo, Y., Sawano, T., Shimada, Y., Kobashi, Y., ... & Tanimoto, T. (2020). Overview and transparency of non-research payments to healthcare organizations and healthcare professionals from pharmaceutical companies in Japan: analysis of payment data in 2016. Health Policy, 124(7), 727-735.
Rasool, S., Ali, M., Shahroz, H. M., Hussain, H. K., & Gill, A. Y. (2024). Innovations in AI-Powered Healthcare: Transforming Cancer Treatment with Innovative Methods. BULLET: Jurnal Multidisiplin Ilmu, 3(1), 118-128.
Reddy, V. V., Vishal Gupta, N., Raghunandan, H. V., & Nitin Kashyap, U. (2014). Quality risk management in pharmaceutical industry: a review. International Journal of Pharm Tech Research, 6(3), 908-914.
Rodríguez-Pérez, J. (2017). Quality risk management in the FDA-regulated industry. Quality Press.
Shanley, T. P., Calvin-Naylor, N. A., Divecha, R., Wartak, M. M., Blackwell, K., Davis, J. M., ... & Barohn, R. (2017). Enhancing Clinical Research Professionals’ Training and Qualifications (ECRPTQ): recommendations for Good Clinical Practice (GCP) training for investigators and study coordinators. Journal of Clinical and Translational Science, 1(1), 8-15.
Souto, E. B., Silva, G. F., Dias-Ferreira, J., Zielinska, A., Ventura, F., Durazzo, A., ... & Santini, A. (2020). Nanopharmaceutics: Part I—Clinical trials legislation and good manufacturing practices (GMP) of nanotherapeutics in the EU. Pharmaceutics, 12(2), 146.
Special Programme for Research, Training in Tropical Diseases, & World Health Organization. (2009). Handbook: good laboratory practice (GLP): quality practices for regulated non-clinical research and development. World Health Organization. Baldeshwiler, A. M. (2003). History of FDA good laboratory practices. The Quality Assurance Journal: The Quality Assurance Journal for Pharmaceutical, Health and Environmental Professionals, 7(3), 157-161.
Subramanian, M., Keshamma, E., Janjua, D., Kumar, D., Kumar, R., Saha, P., ... & Rao, S. (2022). Quality risk management approach for drug development and its future prospectives. Journal for Research in Applied Sciences and Biotechnology, 1(3), 166-177.
Sung, C. (2022). Product integrity for patient safety: a Pfizer case study. In Brand Protection and the Global Risk of Product Counterfeits (pp. 218-226). Edward Elgar Publishing.
Tibbs, C. (2024). Case Study Analysis: Exploring Johnson & Johnson's 1982 Tylenol Contamination Crisis and Ongoing Talcum Powder Crisis Through The Six Principles of Crisis and Emergency Risk Communication.
Timóteo, M., Lourenço, E., Brochado, A. C., Domenico, L., da Silva, J., Oliveira, B., ... & Alves, G. (2021, June). Digital management systems in academic health sciences laboratories: A scoping review. In Healthcare (Vol. 9, No. 6, p. 739). MDPI.
Verma, K. (2013). Base of a research: good clinical practice in clinical trials. J Clin Trials, 3(1), 100-28.
Waldron, K. (2017). Managing risk to the patient: recoding quality risk management for the pharmaceutical and biopharmaceutical industries.
Wingate, G. (Ed.). (2016). Pharmaceutical computer systems validation: quality assurance, risk management and regulatory compliance.
World Health Organization. (2005). Handbook for good clinical research practice (GCP): guidance for implementation.
World Health Organization. (2007). WHO guidelines on good manufacturing practices (GMP) for herbal medicines. World Health Organization.
World Health Organization. (2024). Quality assurance of pharmaceuticals: a compendium of guidelines and related materials. Volume 2. Good manufacturing practices and inspection. World Health Organization.
Yingngam, B. (2024). Medical Statistics in Drug Development and Regulatory Approval. In Exploring Medical Statistics: Biostatistics, Clinical Trials, and Epidemiology (pp. 57-110). IGI Global.
Young, J. H. (2014). Pure food: securing the Federal Food and Drugs Act of 1906 (Vol. 1004). Princeton University Press.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Judith Nwoke
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
